- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT05006404
Az Autus Valve korai megvalósíthatósági tanulmánya
Autus állítható méretű szelep sebészeti tüdőbillentyű cseréhez Korai megvalósíthatósági tanulmány
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.
The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
California
-
Los Angeles, California, Egyesült Államok, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, Egyesült Államok, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Egyesült Államok, 30322
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Egyesült Államok, 60611
- Ann and Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Egyesült Államok, 48109
- University of Michigan - Mott Children's Hospital
-
-
New York
-
New York, New York, Egyesült Államok, 10032
- Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
-
-
North Carolina
-
Durham, North Carolina, Egyesült Államok, 27703
- Duke University
-
-
Ohio
-
Columbus, Ohio, Egyesült Államok, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Egyesült Államok, 19104
- Children's Hospital of Philadelphia
-
-
Utah
-
Salt Lake City, Utah, Egyesült Államok, 84113
- University of Utah - Intermountain Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Egyesült Államok, 98105
- Seattle Children's Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.
-
Age 18 months to 16 years.
-
Male or female.
-
Subject has a native or repaired right ventricular outflow tract.
-
Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).
-
Subject has at least one of the following echocardiographic findings:
- Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
- Moderate or greater pulmonary regurgitation;
- Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
-
Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).
-
Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.
-
Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.
Exclusion Criteria:
Candidates will be excluded from the study if any of the following conditions are met:
- Subject requires valve replacement in a non-pulmonary position.
- Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
- Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
- Subject has pulmonary atresia and major aortopulmonary collaterals.
- Subject has significant peripheral pulmonary artery stenosis.
- Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
- Subject has active endocarditis or a history of infective endocarditis.
- Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
- Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
- Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
- Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
- Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
- Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
- Subject needs emergency cardiac or vascular surgery or intervention.
- Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
- Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
- Subject or parent/legal representative refuses blood transfusions.
- Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
- Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Autus Valve Arm
Pulmonary Valve Replacement Surgery with the Autus Valve |
Pulmonary valve replacement surgery with the Autus Valve |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Valve Implantation Primary Safety Endpoint
Időkeret: 30 Days post-valve implantation
|
Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:
|
30 Days post-valve implantation
|
|
Valve Implantation Primary Effectiveness Endpoint
Időkeret: 6 Months post-valve implantation
|
Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:
|
6 Months post-valve implantation
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Other Safety Outcome - Composite
Időkeret: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:
|
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Mortality
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Mortality, including: all cause, cardiac-related, procedure-related and device-related |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve Thrombosis
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Valve thrombosis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Thromboembolism
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Thromboembolism |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Cardiac or Valve Intervention
Időkeret: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Other cardiac or valve intervention (surgical or transcatheter) |
30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Major Hemorrhage
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Major hemorrhage |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Endocarditis
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Endocarditis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Hemolysis
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Hemolysis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Device Explantation
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Device explantation |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Adverse Events (AE)
Időkeret: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Adverse events |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve/Stent Fracture
Időkeret: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure. |
pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
Időkeret: Immediately Post-Valve Implant Procedure
|
To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):
|
Immediately Post-Valve Implant Procedure
|
|
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
Időkeret: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Pulmonary Stenosis Grade
Időkeret: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Right Ventricular Measures
Időkeret: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Left Ventricular Measures
Időkeret: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Modified Ross Functional Classification
Időkeret: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Modified Ross Functional Class as assessed by the Site Investigators |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - PedsQL - Cardiac Module
Időkeret: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel. |
Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
|
Other Post-Implant Valve Expansion Safety Outcome - Composite
Időkeret: 30 days after each post-implant valve expansion procedure
|
Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:
|
30 days after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
Időkeret: Immediately after each post-implant valve expansion procedure
|
To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:
|
Immediately after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
Időkeret: 6 months after each post-implant valve expansion procedure
|
Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:
|
6 months after each post-implant valve expansion procedure
|
Együttműködők és nyomozók
Szponzor
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- AUT-CP-001
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .